vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Ranger Energy Services, Inc.（RNGR）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是Ranger Energy Services, Inc.的1.3倍（$183.1M vs $142.2M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 2.3%，领先11.1%），Ranger Energy Services, Inc.同比增速更快（-0.6% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $17.1M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs 1.9%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Ranger Energy Services是北美领先的陆上油田服务提供商，为上游油气运营商提供完井、修井、钻机作业及产能优化等全套解决方案，业务主要覆盖美国本土的页岩和致密资源开采作业区。
AMPH vs RNGR — 直观对比
营收规模更大
AMPH
是对方的1.3倍
$142.2M
营收增速更快
RNGR
高出1.2%
-1.8%
净利率更高
AMPH
高出11.1%
2.3%
自由现金流更多
AMPH
多$7.5M
$17.1M
两年增速更快
AMPH
近两年复合增速
1.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $142.2M |
| 净利润 | $24.4M | $3.2M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | 2.3% |
| 净利率 | 13.3% | 2.3% |
| 营收同比 | -1.8% | -0.6% |
| 净利润同比 | -35.7% | -44.8% |
| 每股收益（稀释后） | $0.51 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHRNGR
| Q4 25 | $183.1M | $142.2M | ||
| Q3 25 | $191.8M | $128.9M | ||
| Q2 25 | $174.4M | $140.6M | ||
| Q1 25 | $170.5M | $135.2M | ||
| Q4 24 | $186.5M | $143.1M | ||
| Q3 24 | $191.2M | $153.0M | ||
| Q2 24 | $182.4M | $138.1M | ||
| Q1 24 | $171.8M | $136.9M |
净利润AMPHRNGR
| Q4 25 | $24.4M | $3.2M | ||
| Q3 25 | $17.4M | $1.2M | ||
| Q2 25 | $31.0M | $7.3M | ||
| Q1 25 | $25.3M | $600.0K | ||
| Q4 24 | $38.0M | $5.8M | ||
| Q3 24 | $40.4M | $8.7M | ||
| Q2 24 | $37.9M | $4.7M | ||
| Q1 24 | $43.2M | $-800.0K |
毛利率AMPHRNGR
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
营业利润率AMPHRNGR
| Q4 25 | 19.4% | 2.3% | ||
| Q3 25 | 13.2% | 2.0% | ||
| Q2 25 | 24.2% | 6.1% | ||
| Q1 25 | 21.9% | 0.7% | ||
| Q4 24 | 24.2% | 6.2% | ||
| Q3 24 | 29.8% | 8.4% | ||
| Q2 24 | 30.3% | 5.3% | ||
| Q1 24 | 27.9% | -0.4% |
净利率AMPHRNGR
| Q4 25 | 13.3% | 2.3% | ||
| Q3 25 | 9.0% | 0.9% | ||
| Q2 25 | 17.8% | 5.2% | ||
| Q1 25 | 14.8% | 0.4% | ||
| Q4 24 | 20.4% | 4.1% | ||
| Q3 24 | 21.1% | 5.7% | ||
| Q2 24 | 20.8% | 3.4% | ||
| Q1 24 | 25.1% | -0.6% |
每股收益（稀释后）AMPHRNGR
| Q4 25 | $0.51 | $0.14 | ||
| Q3 25 | $0.37 | $0.05 | ||
| Q2 25 | $0.64 | $0.32 | ||
| Q1 25 | $0.51 | $0.03 | ||
| Q4 24 | $0.74 | $0.24 | ||
| Q3 24 | $0.78 | $0.39 | ||
| Q2 24 | $0.73 | $0.21 | ||
| Q1 24 | $0.81 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $10.3M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $300.1M |
| 总资产 | $1.6B | $419.3M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHRNGR
| Q4 25 | $282.8M | $10.3M | ||
| Q3 25 | $276.2M | $45.2M | ||
| Q2 25 | $231.8M | $48.9M | ||
| Q1 25 | $236.9M | $40.3M | ||
| Q4 24 | $221.6M | $40.9M | ||
| Q3 24 | $250.5M | $14.8M | ||
| Q2 24 | $217.8M | $8.7M | ||
| Q1 24 | $289.6M | $11.1M |
总债务AMPHRNGR
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $0 | ||
| Q3 24 | $596.4M | $0 | ||
| Q2 24 | $586.9M | $0 | ||
| Q1 24 | $594.0M | $0 |
股东权益AMPHRNGR
| Q4 25 | $788.8M | $300.1M | ||
| Q3 25 | $776.7M | $270.0M | ||
| Q2 25 | $757.5M | $276.9M | ||
| Q1 25 | $751.3M | $272.6M | ||
| Q4 24 | $732.3M | $273.8M | ||
| Q3 24 | $727.7M | $267.6M | ||
| Q2 24 | $713.3M | $260.5M | ||
| Q1 24 | $672.4M | $261.7M |
总资产AMPHRNGR
| Q4 25 | $1.6B | $419.3M | ||
| Q3 25 | $1.7B | $372.8M | ||
| Q2 25 | $1.6B | $381.7M | ||
| Q1 25 | $1.6B | $376.5M | ||
| Q4 24 | $1.6B | $381.6M | ||
| Q3 24 | $1.5B | $373.9M | ||
| Q2 24 | $1.5B | $359.6M | ||
| Q1 24 | $1.6B | $355.5M |
负债/权益比AMPHRNGR
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 0.00× | ||
| Q3 24 | 0.82× | 0.00× | ||
| Q2 24 | 0.82× | 0.00× | ||
| Q1 24 | 0.88× | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $24.1M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $17.1M |
| 自由现金流率自由现金流/营收 | 13.4% | 12.0% |
| 资本支出强度资本支出/营收 | 4.5% | 4.9% |
| 现金转化率经营现金流/净利润 | 1.35× | 7.53× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $42.9M |
8季度趋势，按日历期对齐
经营现金流AMPHRNGR
| Q4 25 | $32.9M | $24.1M | ||
| Q3 25 | $52.6M | $13.6M | ||
| Q2 25 | $35.6M | $20.7M | ||
| Q1 25 | $35.1M | $10.6M | ||
| Q4 24 | $29.0M | $32.7M | ||
| Q3 24 | $60.0M | $17.7M | ||
| Q2 24 | $69.1M | $22.1M | ||
| Q1 24 | $55.3M | $12.0M |
自由现金流AMPHRNGR
| Q4 25 | $24.6M | $17.1M | ||
| Q3 25 | $47.2M | $8.0M | ||
| Q2 25 | $25.0M | $14.4M | ||
| Q1 25 | $24.4M | $3.4M | ||
| Q4 24 | $16.6M | $27.3M | ||
| Q3 24 | $46.2M | $10.8M | ||
| Q2 24 | $63.1M | $6.8M | ||
| Q1 24 | $46.5M | $5.5M |
自由现金流率AMPHRNGR
| Q4 25 | 13.4% | 12.0% | ||
| Q3 25 | 24.6% | 6.2% | ||
| Q2 25 | 14.3% | 10.2% | ||
| Q1 25 | 14.3% | 2.5% | ||
| Q4 24 | 8.9% | 19.1% | ||
| Q3 24 | 24.1% | 7.1% | ||
| Q2 24 | 34.6% | 4.9% | ||
| Q1 24 | 27.1% | 4.0% |
资本支出强度AMPHRNGR
| Q4 25 | 4.5% | 4.9% | ||
| Q3 25 | 2.8% | 4.3% | ||
| Q2 25 | 6.1% | 4.5% | ||
| Q1 25 | 6.3% | 5.3% | ||
| Q4 24 | 6.7% | 3.8% | ||
| Q3 24 | 7.2% | 4.5% | ||
| Q2 24 | 3.3% | 11.1% | ||
| Q1 24 | 5.1% | 4.7% |
现金转化率AMPHRNGR
| Q4 25 | 1.35× | 7.53× | ||
| Q3 25 | 3.03× | 11.33× | ||
| Q2 25 | 1.15× | 2.84× | ||
| Q1 25 | 1.39× | 17.67× | ||
| Q4 24 | 0.76× | 5.64× | ||
| Q3 24 | 1.48× | 2.03× | ||
| Q2 24 | 1.82× | 4.70× | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RNGR
| High Specification Rigs | $92.3M | 65% |
| Processing Solutions And Ancillary Services | $37.5M | 26% |
| Wireline Services | $12.4M | 9% |
